[Correspondence] Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis

Glucagon-like peptide-1 (GLP-1) receptor agonists are commonly used as second-to-third line drugs in the treatment of type 2 diabetes.1 They include exenatide and lixisenatide, which are structurally similar to exendin-4, a peptide found in the saliva of the Gila monster lizard (exendin-based GLP-1 receptor agonists). In contrast, liraglutide, dulaglutide, albiglutide, and semaglutide are structurally analogous to the human GLP-1 molecule (human-analogue GLP-1 receptor agonists).2 Although potentially life-threatening allergies, such as anaphylactic reactions, have been documented with all GLP-1 receptor agonists,2,3 whether differences exist between exendin-based and human-analogue GLP-1 receptor agonists is unclear.

Bekijk het originele bericht